Voyager Therapeutics Shares Outstanding 2014-2021 | VYGR
Voyager Therapeutics shares outstanding from 2014 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Voyager Therapeutics Annual Shares Outstanding
(Millions of Shares) |
| 2020 |
37 |
| 2019 |
36 |
| 2018 |
32 |
| 2017 |
27 |
| 2016 |
25 |
| 2015 |
4 |
| 2014 |
1 |
| 2013 |
0 |
Voyager Therapeutics Quarterly Shares Outstanding
(Millions of Shares) |
| 2021-06-30 |
38 |
| 2021-03-31 |
38 |
| 2020-12-31 |
37 |
| 2020-09-30 |
38 |
| 2020-06-30 |
37 |
| 2020-03-31 |
37 |
| 2019-12-31 |
36 |
| 2019-09-30 |
37 |
| 2019-06-30 |
38 |
| 2019-03-31 |
33 |
| 2018-12-31 |
32 |
| 2018-09-30 |
32 |
| 2018-06-30 |
32 |
| 2018-03-31 |
32 |
| 2017-12-31 |
27 |
| 2017-09-30 |
26 |
| 2017-06-30 |
26 |
| 2017-03-31 |
26 |
| 2016-12-31 |
25 |
| 2016-09-30 |
25 |
| 2016-06-30 |
25 |
| 2016-03-31 |
25 |
| 2015-12-31 |
4 |
| 2015-09-30 |
1 |
| 2015-06-30 |
1 |
| 2015-03-31 |
1 |
| 2014-12-31 |
1 |
| 2014-09-30 |
1 |
| 2014-06-30 |
1 |
| 2014-03-31 |
0 |
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.112B |
$0.171B |
|
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
|
